Protective effect of higenamine ameliorates collagen-induced arthritis through heme oxygenase-1 and PI3K/Akt/Nrf-2 signaling pathways
Authors:
- 20 September 2016
- journal article
- Published by Spandidos Publications in Experimental and Therapeutic Medicine
- Vol. 12 (5) , 3107-3112
Abstract
Existing in Ranunculaceae Aconitum and tomato, with the chemical name 1‑phydroxybenzyl‑1,2,3,4‑tetrahy‑droisoquinoline, higenamine is widely distributed in China. Higenamine's anti‑inflammatory, antioxidant and anti‑apoptotic effects have been identified in previous studies. The present study attempted to determine the protective effect of higenamine against collagen‑induced arthritis through heme oxygenase‑1 (HO‑1) and PI3K/Akt/Nrf‑2 signaling pathways. A type II collagen (CII)‑induced arthritis (CIA) model was established and clinical arthritis scores were used to appraise the curative effect of higenamine. Inflammatory reactions, oxidative damage and caspase‑3/9 activation were detected using specific ELISA kits. In addition, western blotting was used to evaluate the expression of HO‑1, Akt and Nrf‑2 protein in CII‑induced CIA mice. In CII‑induced CIA mice, the clinical arthritis scores, inflammatory reactions, oxidation damage and caspase‑3/9 activation were increased and activated. The results demonstrated that treatment with higenamine significantly reduced the elevation of clinical arthritis scores (P<0.01), and suppressed the promotion of inflammatory reactions, oxidation damage and caspase‑3/9 activation. Furthermore, higenamine significantly increased HO‑1 protein expression (P<0.01) and upregulated the PI3K/Akt/Nrf‑2 signal pathway in CII‑induced CIA mice. Collectively, it is concluded that higenamine protects against CII‑induced CIA through the induction of HO‑1 and the upregulation of the PI3K/Akt/Nrf‑2 signaling pathway. In conclusion, higenamine may be a beneficial drug for protecting against CIA.Keywords
This publication has 24 references indexed in Scilit:
- Efficacy and safety of tabalumab, an anti-B-cell-activating factor monoclonal antibody, in patients with rheumatoid arthritis who had an inadequate response to methotrexate therapy: results from a phase III multicentre, randomised, double-blind studyAnnals of the Rheumatic Diseases, 2015
- Maintenance of remission following 2 years of standard treatment then dose reduction with abatacept in patients with early rheumatoid arthritis and poor prognosisAnnals of the Rheumatic Diseases, 2015
- Collagen-induced arthritis: severity and immune response attenuation using multivalent N-acetyl glucosamineClinical and Experimental Immunology, 2014
- A phase I study on pharmacokinetics and pharmacodynamics of higenamine in healthy Chinese subjectsActa Pharmacologica Sinica, 2012
- 1H NMR-based metabolomic analysis for identifying serum biomarkers to evaluate methotrexate treatment in patients with early rheumatoid arthritisExperimental and Therapeutic Medicine, 2012
- An essential role for mast cells as modulators of neutrophils influx in collagen-induced arthritis in the mouseLaboratory Investigation, 2011
- Norcoclaurine Synthase: Mechanism of an Enantioselective Pictet-Spengler Catalyzing EnzymeMolecules, 2010
- Differences between the United States and the United Kingdom in the treatment of rheumatoid arthritis: analyses from a hand arthroplasty trialClinical Rheumatology, 2010
- Ultrasound-guided intra-articular injections in the wrist in patients with rheumatoid arthritis: a double-blind, randomised controlled studyAnnals of the Rheumatic Diseases, 2008
- Immunopharmacological Studies on Collagen-Induced Arthritis in Dark Agouti (DA) Rats.The Japanese Journal of Pharmacology, 1997